98%
921
2 minutes
20
Background: Recent observational studies have reported that prompt initiation of single-inhaler triple therapy after a COPD exacerbation is more effective than delayed initiation. We show that their study design, by "peeking into the future" to define the timing of treatment initiation, introduces time-related biases, particularly protopathic bias. These biases can be avoided using the "cloning" approach to emulate a randomized trial approach.
Methods: We formed a cohort of patients with COPD who had an exacerbation (index) after September 2017, using the United Kingdom's Clinical Practice Research Datalink (CPRD). Using the "cloning" trial emulation technique, each subject was assigned to both the prompt and the delayed initiator arms as of the index date and censored according to their treatment over time. The Cox model was used to compare the incidence of the first exacerbation after the index exacerbation, over one year, after weighing by inverse probability of censoring. We also replicated the biased approach of the recent studies, based on peeking into the future.
Results: The cohort included 91,958 eligible subjects who had an exacerbation, generating 91,958 prompt initiator clones and 91,958 delayed initiator clones. The hazard ratio (HR) of a moderate or severe exacerbation, comparing prompt versus delayed initiators, was 0.98 (95% CI: 0.80-1.19), while it was 1.26 (95% CI: 0.81-1.96) for severe exacerbation. The replication of the time-related biased approach comparing prompt with delayed initiation resulted, correspondingly, in HRs of 0.73 (95% CI: 0.65-0.81) and 0.58 (95% CI: 0.46-0.74).
Conclusion: Using a trial emulation approach, prompt treatment with single-inhaler triple therapy after a COPD exacerbation was not more effective than delayed treatment at reducing the incidence of subsequent exacerbations. The method used by previous studies, suggesting significant effectiveness with prompt treatment initiation, was affected by time-related biases induced by peeking into the future. A randomized controlled trial can confirm these findings.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12239917 | PMC |
http://dx.doi.org/10.2147/COPD.S527497 | DOI Listing |
Cell Signal
September 2025
School of Forensic Medicine, Xinxiang Medical University, Xinxiang, Henan 453003, People's Republic of China.
Triple-negative breast cancer (TNBC) presents a formidable therapeutic challenge due to its aggressive behavior, molecular heterogeneity, and lack of actionable targets. This study identifies activation-induced cytidine deaminase (AID) as a pivotal epigenetic driver reprogramming the tumor microenvironment (TME) via non-canonical regulation of NOTCH signaling. Mechanistically, AID recruits histone acetyltransferase 1 (HAT1) to form a chromatin-remodeling complex that binds the JAG1 promoter region (-1.
View Article and Find Full Text PDFSci Adv
September 2025
The Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.
Influenza A viruses remain a global health threat, yet no universal antibody therapy exists. Clinical programs have centered on neutralizing mAbs, only to be thwarted by strain specificity and rapid viral escape. We instead engineered three non-neutralizing IgG2a mAbs that target distinct, overlapping epitopes within the conserved N terminus of the M2 ectodomain (M2e).
View Article and Find Full Text PDFSci Transl Med
September 2025
Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Precision Cancer Medicine Center, Fudan University Shanghai Cancer Center, Shanghai 200032, P. R. China.
Triple-negative breast cancers (TNBCs) lack predictive biomarkers to guide immunotherapy, especially during early-stage disease. To address this issue, we used single-cell RNA sequencing, bulk transcriptomics, and pathology assays on samples from 171 patients with early-stage TNBC receiving chemotherapy with or without immunotherapy. Our investigation identified an enriched subset of interferon (IFN)-induced CD8 T cells in early TNBC samples, which predict immunotherapy nonresponsiveness.
View Article and Find Full Text PDFCancer Res Commun
September 2025
Spanish National Cancer Research Centre, Madrid, Madrid, Spain.
Purpose: Advanced, pre-treated TNBC has a dismal prognosis and lacks effective options beyond standard cytotoxics. We previously showed, via phosphoproteomic screening, that CDK6 and ERK hyperactivation are linked to adverse outcomes and represent actionable targets. This prompted us to evaluate palbociclib and binimetinib in advanced TNBC after one or two prior therapies.
View Article and Find Full Text PDFNanoscale
September 2025
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China.
Correction for 'Nanoparticles modified by triple single chain antibodies for MRI examination and targeted therapy in pancreatic cancer' by Jinmao Zou , , 2020, , 4473-4490, https://doi.org/10.1039/C9NR04976B.
View Article and Find Full Text PDF